-
Insulin degludec (INN/USAN) is an ultralong-acting
basal insulin analogue that was
developed by Novo
Nordisk under the
brand name Tresiba. It is administered...
-
Insulin degludec/liraglutide, sold
under the
brand name Xultophy, is a fixed-dose
combination medication for the
treatment of
adults with type 2 diabetes...
-
Insulin degludec/insulin aspart, sold
under the
brand name Ryzodeg, is a fixed-dose
combination medication for the
treatment of
diabetes mellitus. It contains...
- A10AE06
Insulin degludec A10AE07
Insulin icodec A10AE30
Combinations A10AE54
Insulin glargine and
lixisenatide A10AE56
Insulin degludec and liraglutide...
- INN"
analogue approved in the USA- 2013 Novo Nordisk's
Tresiba "insulin
degludec INN"
analogue approved in
Europe (EMA with
additional monitoring] Walton...
-
comparing insulin glargine to NPH insulin,
insulin detemir or
insulin degludec in the
management of type 1
diabetes in
either adults or
children over...
- diabetes. Its
glycemic control and
safety were
found similar to
insulin degludec in a
phase II trial. A
systematic review and
metanalysis of
insulin efsitora...
- (compared to 25
hours of the
previous longest-acting
insulin analogue insulin degludec),
making it a once-w****ly
basal insulin. Like insulin,
icodec is composed...
-
clinical use,
tirzepatide was
superior to dulaglutide, semaglutide,
insulin degludec, and
insulin glargine in
improving blood sugar and obesity. In a phase...
-
Insulin glargine (Lantus)
Insulin detemir (Levemir)
Insulin degludec (Tresiba)
Insulin degludec is
sometimes classed separately as an "ultra-long" acting...
